EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Artemisinin and its derivatives for metabolic syndrome: From multi‑target mechanisms to translational opportunities (Review)

Shuo Cao, Mo Yang, Siyu Qu, Jinsong Wu, Jiaheng Li, Ying Zhao

Molecular Medicine Reports · 2026

DOI: 10.3892/mmr.2026.14026 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, 2026. Verfasst von Shuo Cao und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China. Hauptthemen laut MEDLINE: Artemisinins, Metabolic Syndrome. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic syndrome (MetS) is a complex of disorders, characterized by insulin resistance accompanied by abdominal obesity, dyslipidemia, hypertension and impaired glucose metabolism. This group of conditions notably increases the risk of type 2 diabetes mellitus and cardiovascular or cerebrovascular diseases and has become a major global public health challenge. Current treatments for MetS often fail to meet clinical needs owing to the limitations associated with single‑target therapies and notable side effects. Artemisinin‑based drugs are primarily used as antimalarial drugs but have garnered widespread attention for their broad biological activities. Preclinical evidence suggests that artemisinin and its derivatives improve insulin sensitivity, regulate lipid metabolism, alleviate chronic inflammation and reshape the gut microbiota by modulating multiple metabolism‑related signaling pathways, including AMP‑activated protein kinase, PI3K/Akt, NF‑κB and Toll‑like receptor 4, indicating a potential therapeutic avenue for MetS. However, most of these findings are derived from cell‑based and animal studies, while direct clinical evidence in patients with MetS remains limited. In the present review, the therapeutic potential and core molecular mechanisms of artemisinin and its derivatives for MetS are summarized and the challenges and opportunities for their future clinical translation are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtemisininsMetabolic SyndromeHumansAnimalsSignal TransductionInsulin ResistanceGastrointestinal MicrobiomeTranslational Research, BiomedicalLipid Metabolism

Stichwörter der Autor:innen

artemisiningut microbiotainflammationinsulin resistancemetabolic syndromemulti‑target mechanisms

Substanzen

Artemisininsartemisinin

Autor:innen und Institutionen

  • College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China.
  • School of Health, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, P.R. China.

Zitieren

APA

Cao, S., Yang, M., Qu, S., Wu, J., Li, J., & Zhao, Y. (2026). Artemisinin and its derivatives for metabolic syndrome: From multi‑target mechanisms to translational opportunities (Review). Molecular Medicine Reports. https://doi.org/10.3892/mmr.2026.14026

Vancouver

Cao S, Yang M, Qu S, Wu J, Li J, Zhao Y. Artemisinin and its derivatives for metabolic syndrome: From multi‑target mechanisms to translational opportunities (Review). Molecular Medicine Reports. 2026. doi:10.3892/mmr.2026.14026

BibTeX
@article{Cao2026,
  author = {Cao, Shuo and Yang, Mo and Qu, Siyu and Wu, Jinsong and Li, Jiaheng and Zhao, Ying},
  title = {Artemisinin and its derivatives for metabolic syndrome: From multi‑target mechanisms to translational opportunities (Review)},
  journal = {Molecular Medicine Reports},
  year = {2026},
  doi = {10.3892/mmr.2026.14026}
}
Kostenlos starten →